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Celebration of the 75th Anniversary of 
Cushing’s Syndrome
IT IS OPPORTUNE THAT THIS ESPECIAL issue of the Brazilian Journal ofEndocrinology and Metabolism comes out just in time to celebrate the
75th anniversary of the original description of the disease that turned out
to be known as Cushing’s syndrome.
Harvey Williams Cushing (April 8, 1869 — October 7, 1939) was
a renowned neurosurgeon at the inception of endocrinology, and is dis-
tinguished today as the “father of modern neurosurgery”.
A graduate of Yale College, Cushing spent most of his academic and
professional life at Johns Hopkins and at Harvard Medical Schools, where
his innovative and skilful approach to neurosurgery, introducing rigid
homeostasis, asepsis, electrocoagulation, and other technical procedures,
reduced mortality rates from brain surgery from 50 to 10% (1).
Cushing was puzzled by a 23-year-old patient that had central obe-
sity with contrasting skinny arms and legs, presence of bruises and large
purplish striae spread upon a very thin, fragile, and almost translucent skin,
a round and plethoric face resembling a “full moon”, prominent accumu-
lation of dorsal fat, described as “buffalo hump”, in addition to hirsutism,
amenorrhea, hypertension, and hyperglycemia.
Although the hypothalamic–pituitary–adrenal axis and its intercon-
nections were barely known at that time, Cushing described this astonish-
ing condition as “pituitary basophilism”. Little was known about adrenal
biosynthesis and corticosteroid production by the “supra renal capsules”.
Cortisol excess, either by primary adrenal production or secondary
to ACTH excess, and its resulting clinical manifestations are the quintes-
sence of Cushing’s syndrome as we know it today. By 1912, however, lit-
tle did Cushing know about these mechanisms when he published his ini-
tial monograph: “The pituitary body and its disorders” (2), in which he
described the case of Minnie G., his first patient with typical stigmata of
hypercortisolism.
However, it was not until 20 years later that Cushing gathered anoth-
er eleven patients with similar clinical characteristics who were reported in
1932 in a yet another seminal work: “Pituitary basophilism” (3).
The florid clinical manifestations were ascertained to some sort of
pituitary abnormality called “basophilism”, even though only three of the
12 reported patients were identified with a pituitary tumor. Indeed, in his
landmark report, Cushing unintentionally described what appears to be the
first cases of a “polyglandular syndrome”, since at autopsy several cases also
presented hyperplasia of the adrenal glands in association with pituitary
adenomas (3).
Most interestingly, another patient from his series, with identical
manifestations, had an adrenal adenoma found at autopsy, but no physio-
logical relationship had been established. Only a few years later adrenal
tumors were shown to cause the syndrome in some cases (4).
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Mayo Clinic, in Rochester, Minnesota, was the
center of several medical events in the late 40s. By
1936, just three years before Harvey Cushing’s death
at the age of 70, Edward Carl Kendall with his group
of chemists was developing a series of studies aiming at
the isolation of crystalline preparations of the adrenal
cortex with biological activity. The structure of sever-
al adrenal steroids was rapidly elucidated and Kendal
and co-workers were designating them in alphabetical
order as they were isolated; compounds A through F
have been prepared and compound E was later identi-
fied as cortisone.
At the same time, Tadeus Reichstein and his
group in Zurich, Switzerland, were conducting similar
studies, but labeling their isolated products with a dif-
ferent terminology, whereas Wintersteiner and Pfiffn-
er, also in the USA, were giving them yet different
names (for example, Kendall’s compound E was
Reichstein’s compound Fa, and Pfiffner’s compound
F), starting a confusing nomenclature that took years
to be clarified.
Finally, the first synthetic adrenocortical steroid
was produced by Reichstein’s group in 1937: 11-deoxy-
corticosterone (DOC). Whereas other 11-deoxy com-
pounds were produced soon thereafter, it took another
six years for Reichstein to synthesize the first 11-oxy-
genated steroid, 11-dehydrocorticosterone or com-
pound A, which was disappointingly devoid of biological
activity in the treatment of Addison’s disease.
However, in 1946, Lewis Sarett working with
Merck laboratories, produced a partial synthesis of the
biologically active product, compound E, and by 1948
this compound, now designated cortisone, was being
synthesized in gram quantities and showing encourag-
ing effects in the control of Addisonian patients.
Another interesting fact took place at Mayo Clin-
ic. Philip Showalter Hench (February 2, 1896 — March
30, 1965) — the first rheumatologist and head of the
Rheumatology Service at Mayo Clinic —, and his group
observed in patients with rheumatoid arthritis (at that
time thought to be caused by some sort of infectious
disease) the beneficial clinical effects of jaundice and
pregnancy. He also observed significant amelioration in
the post-operative period following some surgeries.
During the Second World War years, Kendall in
collaboration with Sarett of Merck, managed to pro-
duce large amounts of compound E. A strategic rese-
arch plan for the industrial development of synthetic
adrenal corticosteroids had been boosted by the US
Government at that critical period, based on the false
premise that Luftwaffe pilots were able to fly at higher
altitudes (above 40.000 feet) because they were being
injected with steroid hormones, and also by informa-
tion obtained from the US Intelligence that German
submarines were transporting huge amounts of cattle
adrenals bought from Argentina. A conference of
endocrinologists, called upon by Merck, discussed the
possible clinical uses of the hormone. Hench, not ini-
tially among the grantees, finally managed to obtain a
5-g supply from James Carlisle and Randolph Major at
Merck, thanks to his friendship with Kendall.
By 1948, they started injecting cortisone prepa-
rations in patients with rheumatoid arthritis and docu-
menting the splendid beneficial effects on muscle stiff-
ness and soreness. The first injection of 50 mg was
administered to a 29-year-old Mrs. Gardner by
Hench’s colleague, Charles Slocumb, on September
21. At that time, the 100-mg per day dose seemed too
large, but both Hench and Kendall were anxious to
not inadvertently underdose. During the next several
months another 12 selected patients received cortisone
injections and experienced dramatic clinical improve-
ments. Scientific communication was published (5)
and immediately circulated in the lay press. In 1950,
Hench, Kendall, and Reichstein were bestowed with
and shared the Nobel Prize in Medicine or Physiology
for their contribution.
Although Thomas Addison is recognized to
inaugurate the modern era of clinical adrenal physiol-
ogy almost 100 years earlier, when he presented his
classic treatise “On Disease of the Supra Renal Cap-
sules” in 1855 (6), the physiological chemistry of
adrenocortical hormones was still largely unknown, as
stated by Robin Fåhraeus, member of the Swedish
Royal Academy of Sciences, when addressing the 1950
Nobel Prize laureates: “Doctor Philip Hench, Profes-
sor Edward Kendall, and Professor Tadeus Reichstein.
Together your researches have contributed to the
enlightenment of the extremely complicated physio-
logical chemistry of the suprarenal glands, which since
their discovery for a long time have been assumed to
play no other part than to fill up the vacuum between
the kidneys and the diaphragm. Your contributions
have already fulfilled the hopes of therapeutic success
in a field hitherto almost inaccessible”.
Several subsequent studies were conducted
around the world confirming the beneficial clinical
effects of cortisone administration in a host of other
inflammatory diseases. Unfortunately, it did not take
too long to observe that such high therapeutic doses
of cortisone also produce a range of significant adverse
effects that were immediately recognized to resemble
those associated with the clinical manifestations
described in Cushing’s pituitary basophilism paper.
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Thus, cortisone excess or hyperadrenocortisonism and
Cushing’s syndrome became synonymous.
Nevertheless, these important historical events
in medicine prompted the recognition of Cushing’s
syndrome as a disorder resulting from glucocorticoid
excess, and a better understanding of the mechanisms
and interplay of the hypothalamic–pituitary–adreno-
cortical axis, as well as the physiologic and pathophys-
iologic affects of natural and synthetic corticosteroids
in the human body, opened a vast new road for inves-
tigation in endocrinology.
This up-to-date especial issue of Endocrinology
and Metabolism (Arquivos Brasileiros de Endocrinolo-
gia & Metabologia) is the first in the series dedicated
to one selected disorder: Cushing’s syndrome. As
guest editors, we were fortunate to be able to count
with the authoritative cooperation of enthusiastic col-
leagues from centers in the UK, USA, Italy, Canada,
Greece, and Brazil. We are indebted to each and every
one of them for sharing with us important new ideas
and concepts on this ever-growing medical complex
that is “Cushing’s syndrome”.
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